MIV Therapeutics Inc. Names Harvard University Interventional Cardiologist Dr. Joseph Carrozza To Scientific Advisory Board; Industry Authority To Help Guide Development Of MIVT’s Unique Coatings For Highly Biocompatible Cardiovascular Stents

ATLANTA--(BUSINESS WIRE)--Sept. 14, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that Joseph P. Carrozza, Jr., M.D., Chief of Interventional Cardiology at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School, a widely recognized expert in the field of interventional cardiology, has joined the Company's Scientific Advisory Board.